NCT00533195 is a Phase 3 clinical trial of 5-Methoxypsoralen in Atopic Dermatitis, sponsored by Medical University of Vienna.

Who is sponsoring NCT00533195?

NCT00533195 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT00533195?

Interventions in NCT00533195: 5-Methoxypsoralen, UVA1 phototherapy.

What condition does NCT00533195 study?

NCT00533195 studies Atopic Dermatitis.

Is NCT00533195 still recruiting?

NCT00533195 is currently completed. Last updated 13 January 2009.

Last reviewed 2009-01-13 · How we verify

NCT00533195

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UVA1 Phototherapy Versus 5-MOP UVA Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis

Completed Phase 3 Last updated 13 January 2009

What this trial tests

Phase 3 trial testing 5-Methoxypsoralen in Atopic Dermatitis in 20 participants. Completed in 1 January 2009.

Timeline

1 October 2007

Primary endpoint
1 January 2009

1 January 2009

Quick facts

Lead sponsor	Medical University of Vienna
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 October 2007
Primary completion	1 January 2009
Estimated completion	1 January 2009
Sites	1 location across Austria

Drugs / interventions tested

5-Methoxypsoralen — full drug profile →
UVA1 phototherapy

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Medical University of Vienna

Who can join

18 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

remission duration after UVA1 phototherapy and after 5-MOP UVA photochemotherapy
Time frame: 12 months

Sponsor's own description

The purpose of this study is to compare the efficacy, tolerability and remission duration of UVA 1 therapy versus 5-MOP UVA photochemotherapy for patients with severe generalized atopic dermatitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phototherapy for atopic eczema.
Musters AH, Mashayekhi S, Harvey J, Axon E, et al · · 2021 · cited 22× · PMID 34709669 · DOI 10.1002/14651858.cd013870.pub2

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00533195 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 13 January 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00533195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing